Literature DB >> 7082464

Acquisition and extinction of continuously and partially reinforced running in rats with lesions of the dorsal noradrenergic bundle.

S Owen, M R Boarder, J A Gray, M Fillenz.   

Abstract

Local injection of 6-hydroxydopamine was used to selectively destroy the dorsal ascending noradrenergic bundle (DB) in rats. Two lesion procedures were used, differing in the extent of depletion of forebrain noradrenaline they produced (greater than 90% or 77%). In Experiments 1-3 the rats were run in a straight alley for food reward on continuous (CR) or partial (PR) reinforcement schedules. The smaller lesion reduced and the larger lesion eliminated the partial reinforcement acquisition effect (i.e. the faster start and run speeds produced by PR during training) and the partial reinforcement extinction effect (PREE, i.e. the greater resistance to extinction produced by PR training); these changes were due to altered performance only in the PR condition. Abolition of the PREE by the larger DB lesion occurred with 50 acquisition trials, but with 100 trials the lesion had no effect. In Experiment 4 rats were run in a double runway with food reward on CR in the second goal box, and on CR, PR or without reinforcement in the first. The larger lesion again eliminated the PREE in the first runway, but did not block the frustration effect in the second runway (i.e. the faster speeds observed in the PR condition after non-reward than after reward in the first goal box). These results are consistent with the hypothesis that DB lesions alter behavioural responses to signals of non-reward, but not to non-reward itself. They cannot be predicted from two other hypotheses: that the DB mediates responses to reward or that it subserves selective attention. Since septal and hippocampal, but not amygdalar, lesions have been reported to produced similar behavioural changes, it is proposed that the critical DB projection for the effects observed in these experiments is to the septo-hippocampal system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082464     DOI: 10.1016/0166-4328(82)90088-2

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  7 in total

1.  The effects of clonidine on the partial reinforcement extinction effect (PREE).

Authors:  G Halevy; J Feldon; I Weiner
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  The effects of intrahippocampal ibotenate on resistance to extinction after continuous or partial reinforcement.

Authors:  L E Jarrard; J Feldon; J N Rawlins; J D Sinden; J A Gray
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

3.  Participation of brainstem monoaminergic nuclei in behavioral depression.

Authors:  Yan Lin; Yasmeen Sarfraz; Ashley Jensen; Adrian J Dunn; Eric A Stone
Journal:  Pharmacol Biochem Behav       Date:  2011-08-26       Impact factor: 3.533

4.  Relationship between up-regulation of nicotine binding sites in rat brain and delayed cognitive enhancement observed after chronic or acute nicotinic receptor stimulation.

Authors:  F A Abdulla; E Bradbury; M R Calaminici; P M Lippiello; S Wonnacott; J A Gray; J D Sinden
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

5.  Effects of RO 15-1788 on a running response rewarded on continuous or partial reinforcement schedules.

Authors:  M Hawkins; J Sinden; I Martin; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Effect of 6-hydroxydopamine-induced lesions of the dorsal noradrenergic bundle on steady-state operant behaviour.

Authors:  M J Morley; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Ibotenate-induced total septal lesions reduce resistance to extinction but spare the partial reinforcement extinction effect in the rat.

Authors:  P J Coffey; J Feldon; S Mitchell; J Sinden; J A Gray; J N Rawlins
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.